Humana Stock Jumps 5%: Guidance Raised as Medical Costs Ease

Humana stock jumped 5.33% on Friday, November 6, 2026, closing at $433.74, after the health insurer beat third-quarter expectations and raised its full-year profit guidance. Revenue rose about 26% to $41.16 billion, ahead of the $40.87 billion analysts expected, and Humana lifted its 2026 adjusted earnings forecast to at least $9.50 a share, from at least $9.00 before.

What happened

Humana reported its third-quarter 2026 results on Friday morning, and the headline numbers were better than Wall Street had braced for. The Louisville-based insurer, one of the largest providers of Medicare Advantage plans in the United States, posted revenue of about $41.2 billion for the quarter, up roughly 26% from a year earlier.

On an adjusted basis, Humana lost $0.70 a share in the quarter. That sounds weak, and it compares with adjusted earnings of $3.24 a share a year ago, but it was much narrower than the loss of about $1.00 to $1.03 a share analysts had penciled in. On a GAAP basis, Humana earned $1.33 a share.

The number investors watched most closely was the benefit ratio — the share of premiums paid out as medical claims. Humana's insurance segment benefit ratio came in at 93.7%, better than the slightly above 94% management had guided. The consolidated benefit ratio was 93.9%.

Why the stock is blowing up

Medical costs are the whole story for health insurers right now, and Humana said those costs came in at the low end of its expected range. Chief Financial Officer Celeste Mellet told analysts that better-than-expected performance in inpatient care and Medicare Part D helped drive the increase in the full-year forecast.

That cost control let Humana raise guidance in a big way. Alongside the adjusted EPS raise to at least $9.50 — above the $9.15 analysts on average expected — the company lifted its GAAP earnings guidance to at least $15.09 a share, from at least $6.52 previously. Seeking Alpha also pointed to strength in CenterWell, Humana's health services segment, as a driver of the beat.

"We have just one headline today and that is, that we are in a good place," Chief Executive Officer Jim Rechtin said on the investor call, according to Barron's.

The move also stood out because Humana is expanding Medicare Advantage enrollment while many rivals are pulling back from the market. Reuters reported that the company is bucking an industrywide retreat from those plans, betting that its pricing and benefit design for 2027 will keep margins moving toward its target.

Key facts

• Stock move: Humana (NYSE: HUM) closed up 5.33% at $433.74 on Friday, November 6, 2026, from $411.79 on Thursday.
• Revenue: About $41.16 billion in Q3, up about 26% year over year, ahead of the $40.87 billion expected.
• Earnings: Adjusted loss of $0.70 a share, narrower than the roughly $1.00 loss expected; GAAP earnings of $1.33 a share.
• Benefit ratio: 93.7% in the insurance segment, better than guidance of slightly above 94%.
• New guidance: Full-year 2026 adjusted EPS of at least $9.50, up from at least $9.00; GAAP EPS of at least $15.09, up from at least $6.52.

Sources: Reuters, Seeking Alpha, Barron's, Market Briefer.

What's next

Humana was clear that the recovery is not finished. Full-year adjusted earnings are still expected to fall from last year because of pressure from Medicare Advantage Star Ratings for Bonus Year 2026. The raise is about costs coming in better than feared, not about that headwind disappearing.

The longer-term test is margins. Humana said its 2027 Medicare Advantage pricing and benefit design should help it progress toward a pre-tax margin of at least 3% in 2028, and it expects a one-time earnings boost in 2028 from stronger ratings. Management plans to lay out that path in more detail at an investor update on December 10.

For now, Friday's verdict was simple: in a week when several big earnings beats were still punished by investors, Humana gave the market the two things it wanted most — lower medical costs and a higher profit forecast — and the shares were rewarded for it. This article reports what happened and how markets reacted; it is not financial advice.

FAQ

Why did Humana stock rise on November 6, 2026?

Humana beat third-quarter expectations and raised its full-year profit guidance after medical costs came in lower than expected, sending the shares up 5.33% to $433.74.

What is Humana's new 2026 earnings guidance?

Humana now expects adjusted earnings of at least $9.50 a share in 2026, up from at least $9.00, and GAAP earnings of at least $15.09 a share, up from at least $6.52.

What were Humana's Q3 2026 results?

Revenue rose about 26% to $41.16 billion, the adjusted loss was $0.70 a share versus about $1.00 expected, GAAP earnings were $1.33 a share, and the insurance benefit ratio was 93.7%.

What is Humana's next investor event?

Humana plans an investor update on December 10 to discuss its path to earnings growth through 2028, including its target of a pre-tax margin of at least 3% in 2028.